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Background: Several cluster-randomized HIV prevention trials aim to demonstrate 
the population-level preventive impact of antiretroviral therapy (ART). 2013 World 
Health Organization (WHO) guidelines raising the ART initiation threshold to CD4 
<500/µL could attenuate these trials’ effect size by increasing ART usage in control 
clusters. Methods: We used a computational model to simulate strategies from a 
hypothetical cluster-randomized HIV prevention trial. The primary model outcome 
was the relative reduction in 24-month HIV incidence between control (ART offered 
with CD4 below threshold) and intervention (ART offered to all) strategies. We 
assessed this incidence reduction using the revised (CD4 <500/µL) and prior (CD4 
<350/µL) control ART initiation thresholds. Additionally, we evaluated changes to 
trial characteristics that could bolster the incidence reduction. Results: With a con-
trol ART initiation threshold of CD4 <350/µL, 24-month HIV incidence under control 
and intervention strategies was 2.46/100 person-years (PY) and 1.96/100 PY, a 
21% reduction. Raising the threshold to CD4 <500/µL decreased the incidence 
reduction by more than one-third, to 12%. Using this higher threshold, moving to 
a 36-month horizon (vs 24-month), yearly control-strategy HIV screening (vs bian-
nual), and intervention-strategy screening every 2 months (vs biannual), resulted in 
a 31% incidence reduction that was similar to effect size projections for ongoing 
trials. Alternate assumptions regarding cross-cluster contamination had the great-
est infl uence on the incidence reduction. Conclusions: Implementing the 2013 
WHO HIV treatment threshold could substantially diminish the incidence reduction 
in HIV population prevention trials. Alternative HIV testing frequencies and trial 
horizons can bolster this incidence reduction, but they could be logistically and 
ethically challenging. The feasibility of HIV population prevention trials should be 
reassessed as the implementation of treatment guidelines evolves. Key words: 
highly active antiretroviral therapy, HIV, prevention, randomized controlled trials 
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Over the past decade, antiretroviral therapy (ART) for HIV infection has greatly reduced HIV-related morbidity and mortality in 
resource-limited settings.1-5 In 2011, the HPTN 052 
trial demonstrated that effective treatment could 
also dramatically reduce the risk of HIV transmis-
sion in stable serodiscordant sexual partnerships.6 
Although the individual preventive impact of ART 
is clear, questions remain regarding the population-
level effect of treatment-as-prevention in different 
settings. Ecological studies have shown confl icting 
results regarding the impact of ART scale-up on 
HIV incidence.7-10 The only nonecological evidence 
of the population-level effect of increasing ART 
coverage comes from a prospective population 
cohort in KwaZulu-Natal, South Africa. Control-
ling for behavioral, demographic, economic, and 
environmental risk factors, individual HIV acquisi-
tion risk declined signifi cantly with increasing ART 
coverage both in the surrounding community11 and 
among household members of the opposite sex.12
To quantify the preventive benefi ts of expanded 
ART access more conclusively and to assess the fea-
sibility of intensive treatment expansion programs, 
several trials of treatment-as-prevention are ongo-
ing13-15 or planned.16,17 In general, these trials aim 
to randomize geographic clusters of a population 
to initiate ART based on national guidelines (con-
trol, typically CD4 <350/µL vs immediately upon 
diagnosis [intervention]); most also incorporate 
frequent routine HIV screening into the interven-
tion. These trials are designed to assess differences 
in HIV incidence between treatment strategies, and 
several are powered to evaluate incidence reduc-
tions of around 30%.13,14
In June 2013, the World Health Organization 
(WHO) released updated guidelines for the use of 
ART, raising the recommended threshold for ART 
initiation from CD4 <350/µL to CD4 <500/µL in 
asymptomatic patients.18 This recommendation 
may prompt a change in national guidelines and 
trial protocols, leading to greater usage of ART 
in control clusters and potentially attenuating the 
difference in incidence between trial arms. Due to 
the longitudinal impact of policy changes, the inci-
dence in the control arm and the incidence reduc-
tion between arms might be lower than planned 
and could thus require some compensation in trial 
design characteristics. We aimed to (a) quantify the 
impact that the revised ART initiation threshold 
could have on the outcomes of cluster-randomized, 
treatment-as-prevention trials and (b) assess how 
changes in trial characteristics could be used to 
augment the observed incidence reduction in the 
context of this policy change.
METHODS
Analytic Overview
We used 2 integrated HIV models to evaluate the 
outcomes of cluster-randomized population pre-
vention trials. We fi rst used the Cost-Effectiveness 
of Preventing AIDS Complications International 
(CEPAC-I) model,5,19,20 a patient-level microsimula-
tion, to project survival, CD4 count, and HIV RNA 
trajectories of infected individuals. These trajecto-
ries then served as input to the HIV Dynamic Epi-
demic Framework (H-DEF) transmission model,21 
a dynamic, open-cohort epidemic simulation.
We loosely modeled the base case of our analysis 
after a simplifi ed version of the Agence Nationale 
de Recherches sur le Sida (ANRS) 12249 trial, an 
ongoing cluster-randomized population preven-
tion trial conducted in rural KwaZulu-Natal, 
South Africa; the trial is powered for an effect 
size of 34%, based on previous detailed modeling 
analyses.13 (The ANRS 12249 trial incorporates a 
phased approach to enrollment and follow-up in 
22 clusters. For simplicity, we do not simulate this 
phased approach and instead assume concurrent 
enrollment and follow-up.12) Per trial protocol, 
we simulated 2 treatment strategies: (1) delayed 
ART initiation (control, at CD4 <350/µL) and (2) 
immediate ART initiation (intervention, at HIV 
diagnosis). Under both strategies, simulated indi-
viduals were offered home-based HIV screening at 
6-month intervals. We projected HIV transmissions 
over a 24-month horizon under the 2 strategies 
and evaluated the relative reduction in cumulative 
HIV incidence between the 2 strategies (hereafter 
referred to as incidence reduction). Next, we assessed 
the impact that raising the control ART initiation 
threshold to CD4 <500/µL would have on this inci-
dence reduction. We then evaluated how changes 
in the HIV screening frequencies and the time 
horizon of the trial could alter the incidence reduc-
tion in the context of this higher ART initiation 
threshold.
Transmission Model
To simulate trial outcomes, we developed a 
deterministic model of HIV transmission dynam-
ics (H-DEF; see the eAppendix for details).21 The 
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randomly from independent distributions of age, 
sex, HIV RNA, and CD4 count. In the absence 
of treatment, individuals experience a monthly 
decline in CD4 count, increasing the risk of oppor-
tunistic diseases (ODs) and HIV-related mortality.
Previously unidentifi ed individuals can be diag-
nosed with HIV in 2 ways: (1) presentation with an 
OD or (2) periodic routine testing. In simulating 
population prevention trials, other mechanisms of 
HIV testing (antenatal care, workplace programs, 
etc) are assumed to be captured under periodic rou-
tine testing. Participants diagnosed via presentation 
with an OD are assumed to accept testing and link 
to care. In the case of routine testing, however, indi-
viduals have a user-defi ned probability of being 
offered/accepting the HIV test and a probability of 
linking to care following a positive test. Those who 
fail to link are eligible for subsequent testing.
Following diagnosis/linkage, simulated 
patients are monitored with CD4 and HIV RNA 
tests at user-specifi ed frequencies. ART is initiated 
when a patient’s observed CD4 count reaches 
a user-defi ned treatment threshold (specifi c to 
each trial strategy) or in the case of tuberculo-
sis or WHO stage 3-4 disease; pregnancy is not 
simulated. Once on ART, patients are stratifi ed 
by adherence level: highly adherent patients have 
a high probability of achieving virologic sup-
pression, whereas poorly adherent patients have 
a low probability.25 While suppressed, patients 
experience monthly gains in CD4 count; they 
are also subject to a monthly probability of regi-
men failure and viral rebound. Failure leads to 
CD4 decline; when failure is diagnosed based on 
observed immunologic and/or virologic crite-
ria,18,26 patients are switched to second-line ART 
or an adherence intervention is initiated. Any 
patient in care may be lost to follow-up; this risk 
declines with increasing adherence. Those who 
are lost to follow-up while on ART are assumed to 
discontinue therapy, but they may resume treat-
ment upon return to care. Lost patients continue 
to contribute to HIV transmission rates within the 
simulated population.
Input Parameters
Transmission model inputs
HIV RNA–specifi c transmission rates (per 100 
person-years [PY] with HIV) were derived from a 
meta-analysis of heterosexual serodiscordant cou-
ple studies (Table 1).22 We incorporated a 3-month 
model tracks a population of HIV-infected and 
susceptible individuals in monthly time-steps over 
the course of an evolving epidemic. The degree of 
infectivity of individuals with HIV is dependent on 
their HIV RNA level, with higher levels associated 
with increased infectivity,22 but it is independent 
of age and sex; during an initial period of acute 
infection, infectivity is increased by a user-specifi ed 
multiple of chronic infection infectivity. In each 
month, the model projects the number of new HIV 
infections based on (a) collective HIV RNA levels 
(and thus infectivity) of the HIV-infected popula-
tion, (b) the current prevalence of HIV, and (c) 2 cal-
ibration parameters controlling HIV RNA–specifi c 
transmission rates and sexual mixing patterns in 
the simulated population (eFigure 1). Individual 
characteristics of the HIV-negative population (age, 
sex, etc) are not modeled explicitly; instead, outside 
data23,24 are used to project population dynamics 
over time. Newly infected individuals are then 
removed from this HIV-nega tive population, incor-
porated into the HIV-infected population, and are 
able to transmit HIV during subsequent monthly 
time-steps.
The H-DEF model itself does not simulate the 
disease progression of individuals with HIV. 
Instead, it relies on the CEPAC-I microsimulation 
to provide trajectories of survival, HIV RNA levels, 
CD4 count, and ART status, all of which are used 
within the transmission model (eFigure 1). As HIV 
testing and treatment policies are changed within 
the CEPAC-I model, these outcome trajectories 
change and the epidemic ramifi cations are pro-
jected by H-DEF.
A common concern in population prevention 
trial design is that of cross-cluster contamination, 
that is, the possibility that participants in a control 
cluster may sexually mix with those in an interven-
tion cluster (and vice versa). To simulate this con-
tamination, H-DEF permits a designated fraction 
of total infectivity from the control participants 
to be applied to the susceptible population in the 
intervention clusters and vice versa. This feature 
captures the effects of participants having sexual 
partners outside of their own cluster type.
Disease Model
CEPAC-I is a stochastic microsimulation of HIV 
disease progression, testing, and treatment (see the 
eAppendix for details).5,19,20 The model generates 
a cohort of HIV-infected individuals by drawing 
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Table 1. Model input parameters and sensitivity analysis ranges
Variable Base case value Range Reference
HIV transmission
Transmissions per 100 PY with HIV
 < 500 copies/mL 0.16 0–0.64 22
 501-3,000 copies/mL 2.06
 3,001-10,000 copies/mL 4.17
 10,001-30,000 copies/mL 8.12
 > 30,000 copies/mL 9.03
Calibrated transmission rate multipliera 1.96 1.57–2.35
Acute infection
 Duration (months) 3 2–6 27,60
 Infectivity relative to unsuppressed 26 18–38
Cross-cluster sexual contacts, % 10 0–20  
HIV test characteristics
 Test interval, months 6 13
 Probability of test offer, % 90 40–99b Assumption based on ref. 32 
 Probability of test consent, % 80
 Probability of linkage to care (if positive), % 70 40–99
Baseline ART adherence, %
 Adherence < 50% 6 43c
 50% ≤ adherence < 95% 57
 Adherence ≥ 95% 37
ART effi cacy
HIV RNA suppressed at 6 months, overall, %d 80 70–87e 43,44c
 Adherence < 5% 0
 Adherence = 50%f 46
 Adherence > 95% 91 80–100
Virologic failure rate after 6 months, per 100 PY
 Adherence < 5% 150 70–230g 43,44c
 Adherence = 50%f 72
 Adherence > 95% 1.6 0.8–2.3g
Loss to follow-up
Loss to follow-up rate, on ART, per 100 PY
 Adherence < 5% 18 9–74g 44,47c
 Adherence = 50%f 10
 Adherence > 95% 1.8 0.9–7.2g
Loss to follow-up rate, pre-ART, per 100 PY
 All adherence levels 18 4–18 47,48c
Note: ART = antiretroviral therapy; PY = person-years.
aThe transmission rate multiplier is used to increase transmission rates observed among heterosexual serodiscordant couples 
to rates refl ective of the general population.
bFor sensitivity analysis, test offer and consent are combined into a single probability with base case value of 72%.
cModel input value derived from primary data described in reference.
dOverall suppression will be lower for second-line ART, as poorly adherent patients are more likely to fail fi rst-line and initiate 
second-line.
eOnly suppression at adherence >95% is varied in sensitivity analysis; overall suppression range indicates the range of overall 
suppression rates produced by variation in suppression at adherence >95%.
fValues for suppression, virologic failure, and loss to follow-up are linearly interpolated for adherence values between 5% and 
95%; the value for 50% is provided.
gIn sensitivity analysis, rates are varied in concert at high and low adherence levels.
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of HIV-infected individuals were assumed to be 
undiagnosed (with 3% acutely infected),37 41% 
were diagnosed but not on ART, 25% were on fi rst-
line ART, and 1% were on second-line ART, based 
on data from the Africa Centre Demographic Infor-
mation System and other South African sources 
(eFigure 2).38-40 Among these baseline states, simu-
lated mean (SD) CD4 varied from 380 (190) cells/
µL for those on ART to 560 (230) cells/µL for those 
with acute infection (Table 2).37,41,42 We assumed 
that individuals who were eligible for but not on 
ART at baseline would initiate therapy with a 
monthly probability of 15%, refl ecting enhanced 
efforts to provide access to ART in the context of 
a trial.13 
ART effi cacy
Six-month virologic suppression was assumed 
to be 91% for patients with adherence >95% 
(defi ned by medication possession ratio) and 0% 
with adherence <5%; linear interpolation was used 
for intermediate adherence levels.43 This leads to 
~80% overall suppression at 6 months, consis-
tent with outcomes in KwaZulu-Natal.44 After 6 
months, virologic failure rates ranged from 1.6 
to 150/100 PY, depending on adherence. Patients 
with virologic rebound on fi rst-line ART received 
an adherence intervention, leading to resuppres-
sion for ~50% of them (see the eAppendix).45 
Those who did not resuppress were switched to 
a second-line regimen, after which there were 2 
additional opportunities to resuppress with adher-
ence interventions of decreasing effi cacy.46 Though 
previous failure to suppress on a regimen is not 
acute HIV infection phase, during which infectiv-
ity is increased 26-fold relative to chronic infec-
tion.27 Per estimates in the ANRS trial protocol, 
we assumed 10% cross-cluster contamination13 (ie, 
10% of participants’ sexual partners will be outside 
of their own cluster type) and varied this widely in 
sensitivity analysis.
Natural history
CD4-specifi c rates of morbidity and mortality 
were from the Cape Town AIDS Cohort.28 Patients 
in care received cotrimoxazole prophylaxis at CD4 
<200/µL,29 generally reducing OD risk.30,31
HIV testing
Per trial protocol, HIV tests were offered every 6 
months in both control and intervention clusters.13 
In each 6-month round of screening, we assumed 
90% of individuals would be offered an HIV test, 
80% would consent to the test, and 70% of those 
testing positive would link to care, which was con-
sistent with testing experience from preliminary 
trial data.32 We account for the “window period” 
of infection by assuming that HIV tests give nega-
tive results during the fi rst month after infection 
(due to acute infection) and have 100% sensitivity 
thereafter.33,34
Population
At baseline, modeled adult (≥15 years) HIV 
prevalence was 23%, which was consistent with 
data from KwaZulu-Natal.35,36 Thirty-three percent 
Table 2. Model input parameters and sensitivity analysis ranges, baseline population 
characteristics
State
Proportion of HIV-infected 
population at baseline,a %37,38 Range
Mean (SD) baseline 
CD4, cells/µLb Range
Acute infection 3 1.5–4.5 560 (230)41 450–750
Undiagnosed, chronic 30 15–45 430 (270)37 300–600
Diagnosed, off ART 41 20–60 390 (220)42 250–500
On fi rst-line ART 25 12–37 380 (190)42 250–500
On second-line ART 1 0–5 380 (190)42 250–500
Note: ART = antiretroviral therapy.
aBaseline population distribution is derived from data in references 34-37 (see eFigure 2).
bCD4 distributions are truncated normal distributions calibrated to match data from references 41 (acute infec-
tion), 37 (undiagnosed, chronic), and 42 (off ART, fi rst-line, and second-line).
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intervention strategy (every 1, 2, 4, or 6 months), 
and extending the trial duration (24-, 36-, or 
48-month horizons). For reporting purposes, we 
selected combinations of these changes to create 3 
composite scenarios:
1. Initial: Screening every 6 months in both 
strategies and a 24-month horizon, refl ect-
ing the initial design of the ANRS 12249 
trial.13
2. Intensifi ed: Screening every 2 months in the 
intervention strategy, yearly screening in the 
control strategy, and a 36-month horizon.
3. Maximal: Monthly screening in the interven-
tion strategy, screening every 3 years in the 
control strategy, and a 48-month horizon.
Testing intervals as short as 1 month in the inter-
vention strategy may not be feasible, but these 
extreme frequencies serve to provide an upper 
limit on the trial incidence reduction.
Certain model parameters were derived from 
sub-Saharan African countries other than South 
Africa. To assess the impact of input parameter 
uncertainty and cross-country variability on our 
conclusions, we projected HIV incidence while 
varying model parameters in both trial strate-
gies over the ranges shown in Tables 1 and 2 and 
eTable1. Additionally, we selected several model 
parameters that could most plausibly be affected 
by the implementation of immediate ART (linkage 
to care, initial suppression on fi rst-line ART, loss to 
follow-up) and varied these parameters by a fac-
tor of ±20% under the intervention strategy only.
RESULTS
Calibration
The model was able to produce a close fi t to his-
torical prevalence, incidence, and ART rollout data 
from 1990 to 2011 in KwaZulu-Natal (Figure 1). At 
the baseline of the analysis in 2013, projected HIV 
incidence was 3.41/100 PY, which was consistent 
with published data estimates from KwaZulu-
Natal.11,49,50 Six months after initiating the trial 
treatment strategies, ART coverage increased to 
50% when an initiation threshold of CD4<350/
µL was used, consistent with levels achieved 
in an intensive home-based testing program in 
KwaZulu-Natal.51
explicitly tracked in the model, failed patients 
have lower probabilities of regaining suppression 
after an increasing number of failure events. This 
feature is intended to capture some of the effects of 
resistance. The development of ART resistance is 
not explicitly modeled.
Loss to follow-up
We used adherence-specifi c relative rates of loss 
to follow-up47 and calibrated the absolute rates to 
match the 4% loss at 12 months on ART observed 
in KwaZulu-Natal.44 As individuals at highest 
risk for loss to follow-up are removed from the 
in-care population over time, overall rates of loss 
to follow-up decline, resulting in 7% lost at 24 
months. Patients ineligible for ART due to high 
CD4 count are subject to a higher risk of loss to 
follow-up across all adherence levels, consistent 
with the 45% pre-ART retention observed in Kwa-
Zulu-Natal.48 Lost patients were assumed to have 
a 0.75% monthly probability of returning to care 
and a 50% probability of return upon experiencing 
an acute OD.
Transmission Model Calibration
Before modeling the cluster-randomized trial, 
the transmission model was calibrated to his-
torical HIV prevalence and incidence trends in 
KwaZulu-Natal35,36,49 using 2 calibration param-
eters governing (1) HIV RNA–specific transmis-
sion rates and (2) sexual mixing patterns in the 
population. The first parameter (Table 1) is used 
to increase the transmission rates observed in 
serodiscordant couple studies to a level reflec-
tive of the overall population, whereas the 
second accounts for the effects of nonrandom 
sexual mixing (eTable 1; see eAppendix for more 
details).
Alternative Trial Characteristics
We examined several potential changes to trial 
protocol that could bolster a trial’s incidence 
reduction in the context of an ART initiation 
threshold of CD4 <500/µL for the control strategy. 
These included alternative settings characterized 
by  differing frequencies of HIV screening in the 
control strategy (every 6, 12, 24, or 36 months), 
increasing the frequency of HIV screening in the 
190 HIV CLINICAL TRIALS  •  15/5  •  SEPT-OCT 2014
A0
5
10
15
20
25
30
1990 1995 2000 2005 2010 2015 2020
A
du
lt 
H
IV
 p
re
va
le
nc
e 
an
d 
in
ci
de
nc
e 
(%
)
Year
ASSA2008
Zaidi, AIDS 2013
Barninghausen, AIDS Res. Hum. Retroviruses 2009
H-DEF model
Historical data and calibration
CD4<350/µL 
CD4<500/µL 
Immediate 
CD4<350/µL 
CD4<500/µL 
Immediate 
B
1990 1995 2000 2005 2010 2015 2020
Year
0
10
20
30
40
50
60
70
80
90
100
A
R
T
 c
ov
er
ag
e 
(%
 o
f H
IV
-in
fe
ct
ed
)
CD4<350/µL 
CD4<500/µL 
Immediate 
Historical data and calibration 
Zaidi, AIDS 2013 
Van Rooyen, JAIDS 2013 
H-DEF model 
Figure 1. HIV Dynamic Epidemic Framework (H-DEF) model calibration and projections. Figure 1A depicts 
historical and projected HIV prevalence and incidence in KwaZulu-Natal from 1990 to 2020 in the H-DEF model, 
compared to 3 outside data sources: (1) the Actuarial Society of South Africa (ASSA) 2008 model,36 (2) adjusted 
HIV prevalence estimates from the Africa Center Demographic Information System,35 and (3) HIV incidence 
estimates from a large population-based longitudinal HIV surveillance study.49 Though the ASSA 2008 model 
gives both lower prevalence and lower incidence estimates than the model calibration, ASSA 2008 is reported 
to underestimate both parameters.61 Figure 1B depicts antiretroviral therapy (ART) coverage in KwaZulu-Natal 
from 2004 to 2020 in the H-DEF model compared to (1) estimates from the Africa Center Demographic Informa-
tion System (Zaidi),35 and (2) initial and 6-month ART coverage estimates from a home-based testing program in 
KwaZulu-Natal,51 used as a rubric for how rapidly ART coverage could increase in the context of home-based 
testing within a trial. In both fi gures, the dashed vertical line indicates the start of the simulated trial. To the right 
of the vertical line are model projections of adult HIV prevalence and incidence and ART coverage with ART 
initiation criteria of CD4 <350/µL (dotted line), CD4 < 500/µL (solid gray line), and immediate (dashed line).
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Alternative Trial Characteristics
In general, greater incidence reductions were 
associated with settings with less frequent HIV 
screening in the control strategy, more frequent 
screening in the intervention strategy, and longer 
trial time horizon (Figure 3). The intensifi ed sce-
nario (Figure 3, middle panel, circle) produced an 
incidence reduction of 31%; the maximal scenario 
(Figure 3, right panel, triangle) produced an inci-
dence reduction of 41%. Similar trends with respect 
to the trial design parameters were observed when 
an ART initiation threshold of CD4 <350/µL 
was used (eFigure 5). Notably, the 3 scenarios 
responded differently to the change from an ART 
initiation threshold of CD4 <350/µL to 500/µL: 
the incidence reduction in the initial scenario 
decreased by a relative 40% (21% to 12%), that of 
the intensifi ed scenario decreased by 17% (37% to 
31%), and that of the maximal scenario decreased 
by only 9% (45% to 41%).
Sensitivity analysis
For all 3 of the trial design scenarios selected, the 
parameter with the greatest impact on the incidence 
reduction was related to cross-cluster contamina-
tion (Figure 2B). When contamination was varied 
between 0% and 20%, the incidence reduction in 
the initial scenario (at a threshold of CD4 <500/µL) 
ranged from 17% to 8%, the incidence reduction in 
the intensifi ed scenario ranged from 42% to 21%, 
and the incidence reduction in the maximal sce-
nario ranged from 55% to 29%. The impact of other 
parameters differed by trial scenario. For example, 
variation in the likelihood of test offer/acceptance 
Initial Trial Design
Over the 24-month horizon, we projected an 
HIV incidence of 2.46/100 PY with the control 
strategy and 1.96/100 PY with the intervention, 
for an incidence reduction of 21%. If the ART ini-
tiation threshold in control clusters were raised 
to CD4 <500/µL, 24-month HIV incidence would 
fall for both strategies due to cross-cluster con-
tamination to 2.17/100PY with the control strategy 
and 1.90/100PY with the intervention, decreas-
ing the incidence reduction between strategies 
by more than a third (incidence reduction = 12%) 
(Table 3, top).
With a control ART threshold of CD4 <350/
µL, 41% of HIV-infected individuals in control 
clusters were not on ART after 12 months; in the 
intervention clusters, only 17% were not on ART. 
This resulted in a relative reduction in individuals 
off ART of 59%. Raising the ART threshold in the 
control strategy attenuated the differences in ART 
coverage between the strategies; with a threshold 
of CD4 <500/µL, the relative reduction in indi-
viduals off ART fell to 43% (Table 3, bottom).
Sensitivity analysis
Raising the control ART threshold to CD4 <500/
µL consistently decreased the incidence reduc-
tion across wide variation in input parameters 
(Figure 2A). At all parameter values evaluated, 
the incidence reduction was lower with a thresh-
old of CD4 <500/µL than with a threshold of 
350/ µL; one-third to one-half of the total inci-
dence reduction was lost when the higher ART 
initiation threshold was used.
Table 3. Base case results
Control strategy ART 
threshold Control Intervention Relative reductiona (%)
Cumulative HIV incidence at 24 months (/100 PY)
CD4 <350/µL 2.46 1.96 21
CD4 <500/µL 2.17 1.90b 12
HIV-infected individuals off ART at 12 months (%)
CD4 <350/µL 41 17 59
CD4 <500/µL 29 17 43
Note: ART = antiretroviral therapy; PY = person-years.
aThe relative reduction in HIV incidence between intervention and control strategies is equivalent to trial effect size.
bDue to cross-cluster contamination, incidence in the intervention strategy is affected by the ART initiation thresh-
old in the control strategy.
192 HIV CLINICAL TRIALS  •  15/5  •  SEPT-OCT 2014
A0 5 10 15 20 25 30
Proportion of cross-cluster
sexual contacts (20% to 0)
Prob. link to care after
positive test (0.4 to 0.99)
Prob. HIV test offer/accept
(0.4 to 0.99)
Monthly prob. ART init., off
ART (0.05 to 0.25)
Acute phase infectiousness
multiplier (38 to 18)
Mean CD4, undiagnosed (300
to 600)
Mean CD4, off ART (250 to
500)
Incidence reduction with intervention strategy over 24-month trial (%)
Threshold: 350/µLThreshold: 500/µL
B
0 10 20 30 40 50 60
Proportion of cross-cluster
sexual contacts (20% to 0)
Duration of acute infection,
mths (2 to 6)
Baseline proportion
undiagnosed (0.15 to 0.45)
Months of false-negative tests
post infection (3 to 0)
Mean CD4, undiagnosed (300
to 600)
Prob. HIV test offer/accept
(0.4 to 0.99)
Prob. link to care after
positive test (0.4 to 0.99)
Incidence reduction with intervention strategy over 24-month trial (%)
Initial, 500/µL Intensified, 500/µL Maximal, 500/µL
* 
Figure 2. Sensitivity analysis on model input parameters. Observed incidence reduction is shown for varying val-
ues of select model input parameters; the 7 parameters with the greatest effect on projected results are shown in 
the fi gure. The width of each horizontal bar indicates the variation in incidence reduction when varying a particular 
model parameter over the range (corresponding left to right) denoted in the label in parentheses on the vertical axis; 
wider bars indicate that the incidence reduction is more sensitive to that particular parameter. Dashed vertical lines 
indicate the incidence reduction observed with base case inputs. Figure 2A shows the incidence reduction with the 
initial scenario at control antiretroviral therapy (ART) initiation thresholds of CD4 <350/µL (light gray) and CD4 <500/µL 
(dark gray). Figure 2B shows the incidence reduction with the initial (dark gray), intensifi ed (medium gray), and maximal 
(light gray) scenarios at a control ART initiation threshold of CD4 <500/µL. *For the initial scenario, the incidence is 
greater with acute infection duration of 2 months or 6 months compared to the base case value of 3 months.
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DISCUSSION
On occasion, policy changes are based on best 
possible evidence that falls short of the “gold stan-
dard” randomized clinical trial. When this occurs, 
clinical trials designed to provide that evidence can 
become that much more challenging to conduct, as 
evidenced by this study. 
Using a dynamic mathematical modeling 
approach, we projected that implementing the ART 
initiation threshold of CD4 <500/µL suggested by 
the new WHO guidelines18 reduces the incidence 
reduction in HIV population prevention trials by 
one-third to one-half. Altered characteristics – espe-
cially more frequent HIV screening in the inter-
vention strategy compared to the control strategy 
– produced greater incidence reductions. Notably, 
we projected that a trial scenario with intervention-
strategy screening every 2 months and control-
strategy screening every year would produce a 31% 
incidence reduction at 36 months, consistent with 
the effect size that several population prevention 
trials are currently powered to detect.13,14
Although we found that differential HIV screen-
ing frequencies could efficiently amplify the 
(40%-99%) or in linkage to care after a positive test 
(40%-99%) altered the incidence reduction in the 
initial scenario over a range of 7%. The intensi-
fi ed and maximal scenarios were comparatively 
insensitive to these parameters, with variation in 
the incidence reduction of 2% or less. Conversely, 
variation in the proportion of the population with 
undiagnosed HIV at baseline altered the incidence 
reduction in the intensifi ed and maximal scenarios 
over ranges of 10% and 11%, while that of the initial 
scenario varied by less than 3%.
When varied in the intervention strategy alone, 
we found that a 20% increase or decrease in the 
rate of loss to follow-up did not alter the incidence 
reduction in any of the scenarios by more than 1% 
compared to the base case. However, variation in 
linkage to care or fi rst-line ART suppression in the 
intervention strategy alone did markedly affect the 
incidence reduction. At an ART threshold of CD4 
<500/µL, reductions in these parameters led to 2% 
to 7% absolute decreases in the incidence reduc-
tion; increases in these parameters increased the 
incidence reduction by 1% to 4% compared to the 
base case (eTable 2).
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Figure 3. Incidence reduction with varying trial characteristics. Projected trial incidence reduc-
tion with an antiretroviral therapy (ART) initiation threshold of CD4 <500/µL and varying com-
binations of control strategy HIV test frequency (6-36 months), intervention strategy HIV test 
frequency (1-6 months), and trial horizon (24-48 months). The shading at each point in the fi gure 
denotes the projected incidence reduction with that combination of trial design characteristics. 
Three scenarios are highlighted for further analysis (see Methods section for descriptions of these 
scenarios): (1) initial, square; (2) intensifi ed, circle; (3) maximal, triangle. The predicted incidence 
reduction for each of these scenarios is shown in the legend.
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arm has been a common barrier to achieving a sig-
nifi cant incidence reduction.53 In this case, overlap 
is manifested in increasing control arm ART cover-
age; in our analysis, a greater overlap (ie, a smaller 
difference in ART coverage between strategies) was 
associated with a diminished incidence reduction. 
These fi ndings imply that ongoing monitoring of 
ART coverage will prove valuable in interpreting 
the results of population prevention trials.
Cross-cluster contamination also proved to be 
highly infl uential on trial outcomes. This fi nding 
highlights the importance of selecting trial set-
tings in which communities are relatively sexually 
isolated (such as rural KwaZulu-Natal),13 and it 
suggests that a priori measurement of the likeli-
hood of contamination (via survey or genetic link-
age testing) will be critical to assessments of the 
feasibility of a given trial. Settings in which a high 
degree of contamination is likely may be suitable 
for studying interventions targeted to negative 
individuals,54 but will likely be inappropriate for 
interventions targeted to persons with HIV.
This analysis has several limitations. First, we 
note that the clinical trial strategies simulated here 
are only loosely based on the ANRS 12249 trial; 
our results should not be interpreted as projections 
of the potential outcome of that trial specifi cally. 
Due to the complexity of our combined disease 
progression and transmission models, we have 
not performed direct trial simulations and did not 
make effect size/sample size calculations. Next, 
our model of HIV transmission is neither age- nor 
sex-stratifi ed and does not explicitly account for 
behavioral factors such as concurrent sexual part-
nerships or sexual networks. Likewise, sex differ-
ences in HIV testing frequency and ART uptake 
are not explicitly modeled. Thus, if trial interven-
tions are rolled-out unevenly to individuals who 
differ in these predictors of transmission risk, our 
model may fail to capture the implications for HIV 
incidence.55 For example, current ART coverage is 
comparatively low among more sexually active 
younger individuals35; increasing coverage in this 
group could lead to a disproportionately large 
reduction in incidence. Additionally, we did not 
model the potential for expanded HIV treatment 
and/or poor ART adherence to produce an increase 
in transmitted drug resistance. Transmitted resis-
tance could affect long-term outcomes of expanded 
ART policies,56 but this omission is unlikely to bias 
our short-term incidence projections. Finally, we 
observed incidence reduction, we recognize that 
implementing this will not be straightforward. 
Increasing testing frequency in intervention arms 
will be logistically challenging (and could lead to 
lower test acceptance), and maintaining reduced 
testing frequencies in control arms may pose 
ethical concerns.52 Because HIV screening is also 
the method of ascertaining trial outcomes, dif-
ferential screening frequencies will also need to 
be accounted for when analyzing results. More-
over, the bolstered incidence reduction may come 
at the cost of interpretability of results. A trial 
in which strategies differ only in the choice of 
ART initiation threshold is defi nitively a trial of 
treatment-as-prevention, and differences between 
the 2 strategies can be attributed to the ART ini-
tiation threshold alone. With differential screening 
rates incorporated as well, some of the incidence 
reduction would clearly be due to HIV testing; 
this would now be a trial of test-and-treat. Further, 
although we did not evaluate additional preven-
tive interventions (male circumcision, condom 
provision, prevention of mother-to-child transmis-
sion, etc), some planned cluster-randomized trials 
will incorporate these into combined interven-
tions, with some varying interventions – including 
testing frequency – across more than 2 arms.14,15 
Extrapolating from our results, we can expect that 
the effect of these combination interventions may 
prove relatively robust to changes in ART initiation 
threshold. However, it will be essential to weigh 
the benefi ts of this bolstered incidence reduction 
against the potential to further complicate the 
interpretation of trial results.
In sensitivity analysis, we found that implement-
ing the new ART initiation threshold produced 
consistent decreases in the incidence reduction 
across a wide range of parameter values; likewise, 
differences between the alternative trial scenarios 
simulated were robust to parameter variation. 
However, absolute incidence reductions were 
particularly sensitive to variation in certain param-
eters. Reductions in the rate of HIV test acceptance, 
the likelihood of linkage-to-care after a positive 
test, and the baseline proportion of the population 
with undiagnosed HIV attenuated the differences 
in ART coverage between the 2 trial strategies 
and thus decreased the incidence reduction. This 
result is consistent with fi ndings from prior trials 
of HIV prevention strategies such as microbicides, 
in which “overlap” of an intervention to the control 
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note that the value of expanded HIV treatment and 
prevention programs will depend on their long-
term population-level costs and clinical impact, 
not just their short-term impact on HIV transmis-
sion.57-59 Thus, the results of this analysis, and of 
the cluster-randomized trials we have modeled, 
will be an imperfect indicator of the full, long-term 
benefi ts of treatment-as-prevention.
Our modeling analysis suggests that increas-
ing the control ART initiation threshold from CD4 
<350/µL to CD4 <500/µL could substantially 
reduce the incidence reduction observed in HIV 
population prevention trials. Even though it may 
take some time for this change to be implemented 
in national treatment guidelines and trial protocols, 
it is critical to begin preparing for it now. The feasi-
bility of ongoing trials may need to be reevaluated, 
and potential changes to trial protocol and sample 
size to preserve effect size should be considered.
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